Registry-listed formulations

Icosapent · chembl:CHEMBL460026

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

6 source entries across 5 studies. This list may not include all unresolved or historical entries.

  • Eicosapentaenoic acidRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • eicosapentaenoic acidRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • LDEPARegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • HDEPARegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Eicosapentaenoic AcidRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • EPARegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
1(17%)
Results Posted
33%(1 trials)
Terminated
1(17%)

Phase Distribution

Phase 3
2
33%
Phase 1/2
1
17%
Phase 1
1
17%
Early Phase 1
1
17%
Phase 4
1
17%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
1(16.7%)
Phase 1Safety & dosage
1(16.7%)
Phase 1/2Combined phases
1(16.7%)
Phase 3Large-scale testing
2(33.3%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(1)
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (16.7%)
Phase 11 (16.7%)
Phase 1/21 (16.7%)
Phase 32 (33.3%)
Phase 41 (16.7%)

Trials by Status

unknown117%
completed350%
terminated117%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
recruitingearly_phase_1

Differential Thrombogenesis by EPA and DHA Mediated by HDL

NCT06494488
terminatedphase_1_2

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

NCT04006847
completedphase_3

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

NCT04221217
completedphase_1

Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress

NCT00014027
unknownphase_3

Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor

NCT01048463
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06494488Early Phase 1

Differential Thrombogenesis by EPA and DHA Mediated by HDL

Recruiting
NCT04006847Phase 1/2

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Terminated
NCT04221217Phase 3

Long-term Safety and Efficacy Study of MND-2119 in Patients With Hypertriglyceridemia

Completed
NCT00014027Phase 1

Effect of Polyunsaturated Fatty Acids on Cardiovascular and Motor Responses Under Stress

Completed
NCT01048463Phase 3

Effect of Enteral Nutrition Rich in Eicosapentaenoic Acid (EPA) on Patients Receiving Chemotherapy for GI Tumor

Unknown
NCT00114595Phase 4

Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia

Completed

All 6 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Small molecule
Total Trials
6

External References

ChEMBL
CHEMBL460026

Names & Codes

Research Codes

EPA 45GRopufa 70omega 3 Eicosapentaenoic Acid